Stephen Hahn, M.D., who served as the commissioner of the FDA for just over a year during the first Trump administration, is taking his extensive regulatory expertise to Turn Therapeutics. As executive clinical and regulatory lead, Hahn will guide the regulatory strategy for GX-03, Turn’s topical eczema treatment that is currently in a phase 2 study.